RESEARCH-USE BIOSIMILAR ANTIBODY
Lenzilumab
Monoclonal antibody · IgG1
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.
TARGETCSF2
YMonoclonal antibody
CATALOGSC-BS-439
CATALOG NUMBERSC-BS-439
MOLECULAR WEIGHTApprox. 145.72 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.
Lenzilumab is a recombinant research-use antibody directed against CSF2.